ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2469

Early Referral and Flare´s Control Prevent Orthopaedic and Hand Surgery Indication in a Dynamic Cohort of Hispanic Early Rheumatoid Arthritis Patients

Irazú Contreras-Yáñez1, Guillermo Guaracha2, Efrain Díaz-Borjón3, Martin Iglesias4 and Virginia Pascual-Ramos5, 1Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 3Orthopedics, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 4Plastic Surgery, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 5Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico, Mexico City, Mexico

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Disease Activity, Hand disorders, orthopaedic, rheumatoid arthritis (RA) and surgery

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) patients from Latin-America present distinctive characteristics when compared to Caucasians, that are known to impact patient´s outcomes. Despite early and more aggressive treatment guidelines recently adopted, some patients require reconstructive joint surgery, considered an indicator of poor prognosis. The objectives of the study were to describe incidence rate of orthopedic and hand surgery indication (OHSI) in a cohort of Mexican Mestizo early RA patients treated with conventional DMARDs according to a T2T strategy and to investigate OHSI predictors.

Methods: Patients enrolled in the cohort had a disease duration of <1 year and complete rheumatic assessments at fixed intervals. Up to February 2018, the cohort comprised 185 RA patients recruited from 2004 onwards, with at least fourteen months of follow-up; 2.7% were dead, 23.3% lost to follow-up and 74% had active follow-up. Charts were reviewed and incidence rate of OHSI was calculated. A nested within a cohort case-control study was designed to investigate predictors; cases (patients with OHSI) were paired to controls (1:4) according to age (± 5 years), sex, baseline RF and ACCP; cumulative disease activity (summarized as DAS28, first sustained remission [SR], time in SR, number of flares and % of follow-up in remission status), cumulative treatment (N° DMARD/patient, patients with corticosteroids and % of time with corticosteroids), and cumulative persistence (N° of patients persistent and % of follow-up patients were persistent) were compared between cases and controls. Logistic regression´s models included baseline and cumulative (up to OHSI or equivalent) variables. Local IRB approved the study.

Results: Patients entering the cohort were predominantly middle-aged (mean±SD age of 38.5±12.9 years) female (87.6%), with (mean±SD) 5.4±2.6 months of disease duration. Up to cut-off, the cohort contributed to 1538 patient-years of follow-up. There were 12 patients with incidental OHSI, at a (mean±SD) follow-up of 85±44.5 months; 9 (75%) received orthopedic surgery indication meanwhile 3 (25%) received hand surgery indication; incident global rate was of 0.8/100 patient-years. Regression models included baseline variables (months of symptom´s disease duration) and cumulative variables (N° of flares/patient, % of follow-up in remission status, N° of patients persistent and % of follow-up patients were persistent with therapy). Longer symptom´s duration at referral to the cohort (OR: 1.313, 95%CI: 1.02-1.68, p=0.032) and higher number of flares (OR: 1.608, 95%CI: 1.05-1.61, p=0.015) were predictors of OHSI. ROC showed that the best cut-off for symptom´s duration and cumulative number of flares to predict OHSI were 6 months (Sensitivity: 0.833; Specificity: 0.665; AUC: 0.746, 95% CI: 0.593-0.899) and 5 flares/patient (Sensitivity: 0.750; Specificity: 0.625; AUC: 0.702, 95% CI: 0.522-0.882), respectively.

Conclusion:

Early referral for appropriated management according to a T2T strategy and flares controls may prevent OHSI in Hispanic early RA patients.


Disclosure: I. Contreras-Yáñez, None; G. Guaracha, None; E. Díaz-Borjón, None; M. Iglesias, None; V. Pascual-Ramos, None.

To cite this abstract in AMA style:

Contreras-Yáñez I, Guaracha G, Díaz-Borjón E, Iglesias M, Pascual-Ramos V. Early Referral and Flare´s Control Prevent Orthopaedic and Hand Surgery Indication in a Dynamic Cohort of Hispanic Early Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/early-referral-and-flares-control-prevent-orthopaedic-and-hand-surgery-indication-in-a-dynamic-cohort-of-hispanic-early-rheumatoid-arthritis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/early-referral-and-flares-control-prevent-orthopaedic-and-hand-surgery-indication-in-a-dynamic-cohort-of-hispanic-early-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology